Clinical Trial Update: Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update evaluates the efficacy of NovoSeven for bleeding prophylaxis in people with hemophilia, including those with inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorder
• Hemophilia with Inhibitors

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 2 | Status: COMPLETED